Patent ID: 11879010
Assignee: THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 2:
3. A method of treating cancer in a subject in need thereof, comprising:
(a) administering to the subject an effective amount of a first antibody or fragment thereof, wherein the first antibody or fragment thereof comprises a first antigen binding portion specific for a first cancer antigen and a targeting ligand,
wherein the first cancer antigen is CD20, the first antigen binding portion is a CD20 binding portion, and the targeting ligand is tetrazine, and
wherein the cancer comprises the CD20 specific for the CD20 binding portion, wherein the CD20 binding portion of the first antibody or fragment thereof binds the CD20 of the cancer; and

(b) administering to the subject of (a) an effective amount of a natural killer (NK) cell comprising a targeting agent specific for the targeting ligand of the first antibody or fragment thereof, wherein the targeting agent is trans-cyclooctene (TCO) and binds in vivo to the targeting ligand of the first antibody or fragment thereof,
thereby treating the cancer in the subject.